Overview

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

Status:
Completed

Trial end date:
2019-05-06

Target enrollment:

Participant gender:

Summary

The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Mirabegron